Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis
Pancreatology · 2026
DOI: 10.1016/j.pan.2026.07.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2026. Verfasst von Hiroya Matsumoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Oral and Maxillo…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Purine-Nucleoside Phosphorylase, Gene Deletion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Abstract (Originalsprache)
BACKGROUND: Methylthioadenosine phosphorylase (MTAP) deletion is a frequent genomic alteration in several cancers and a potential therapeutic vulnerability. However, its prevalence and clinical significance in pancreatic cancer remain insufficiently characterized. METHODS: We retrospectively analyzed 8834 patients with pancreatic cancer profiled by FoundationOne® CDx in a nationwide genomic cohort. MTAP-deleted and non-deleted groups were compared for clinicopathological characteristics, co-occurring genomic alterations, tumor mutational burden (TMB), microsatellite instability (MSI), overall survival (OS), and treatment response to first- and second-line chemotherapies. RESULTS: MTAP deletion was identified in 27.3% of pancreatic cancers, with high frequencies in pancreatic ductal adenocarcinoma (PDAC) (28.0%) and adenosquamous carcinoma (35.0%). MTAP deletion strongly co-occurred with CDKN2A/2B deletion and was associated with major driver alterations (KRAS, TP53, SMAD4), while showing no association with high TMB or MSI. In PDAC, the median OS was significantly shorter in the MTAP-deleted group compared with the non-deleted group (24.3 vs. 29.9 months; P < 0.0001). However, CDKN2A-deleted subcohort analysis revealed that MTAP deletion was not associated with OS (HR: 0.96; 95% CI: 0.85-1.08). Furthermore, the objective response and disease control rates to gemcitabine plus nab-paclitaxel or FOLFIRINOX were comparable between the groups. CONCLUSIONS: MTAP deletion is a frequent genomic alteration in pancreatic cancer. Although it was not an independent prognostic or chemotherapy-predictive biomarker, our comprehensive clinicogenomic findings provide a foundation for future evaluation of MTAP-focused therapeutic strategies in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Oral and Maxillofacial Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Ele…
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan.
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
- Department of Oral and Maxillofacial Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan; Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Förderung
- Nagoya University
Zitieren
APA
Matsumoto, H., Mizuno, K., Kondo, C., Kawashima, H., Hibi, H., & Ando, Y. (2026). Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis. Pancreatology. https://doi.org/10.1016/j.pan.2026.07.015
Vancouver
Matsumoto H, Mizuno K, Kondo C, Kawashima H, Hibi H, Ando Y. Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis. Pancreatology. 2026. doi:10.1016/j.pan.2026.07.015
BibTeX
@article{Matsumoto2026,
author = {Matsumoto, Hiroya and Mizuno, Kazuyuki and Kondo, Chiaki and Kawashima, Hiroki and Hibi, Hideharu and Ando, Yuichi},
title = {Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis},
journal = {Pancreatology},
year = {2026},
doi = {10.1016/j.pan.2026.07.015}
}
EUVIMED